Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-05-31
2010-06-29
Steadman, David J (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C530S350000
Reexamination Certificate
active
07745391
ABSTRACT:
A human thrombospondin 1 protein, polynucleotide encoding the protein, and pharmaceutical composition thereof.
REFERENCES:
patent: 4215051 (1980-07-01), Schroeder et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4704692 (1987-11-01), Ladner
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4868103 (1989-09-01), Stavrianopoulos et al.
patent: 4873316 (1989-10-01), Meade et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 4987071 (1991-01-01), Cech et al.
patent: 5093246 (1992-03-01), Cech et al.
patent: 5116742 (1992-05-01), Cech et al.
patent: 5143854 (1992-09-01), Pirrung
patent: 5208020 (1993-05-01), Chari et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5225539 (1993-07-01), Winter
patent: 5272057 (1993-12-01), Smulson et al.
patent: 5283317 (1994-02-01), Saifer et al.
patent: 5288514 (1994-02-01), Ellman
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5384261 (1995-01-01), Winkler et al.
patent: 5459039 (1995-10-01), Modrich et al.
patent: 5475092 (1995-12-01), Chari et al.
patent: 5498531 (1996-03-01), Jarrell
patent: 5510270 (1996-04-01), Fodor et al.
patent: 5527681 (1996-06-01), Holmes
patent: 5571509 (1996-11-01), Comoglio et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5585499 (1996-12-01), Chari et al.
patent: 5631169 (1997-05-01), Lakowicz et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5695937 (1997-12-01), Kinzler et al.
patent: 5846545 (1998-12-01), Chari et al.
patent: 5854033 (1998-12-01), Lizardi
patent: 5876742 (1999-03-01), Cochrum et al.
patent: 6033862 (2000-03-01), Matsuda et al.
patent: 6049728 (2000-04-01), Chou et al.
patent: 6727063 (2004-04-01), Lander et al.
patent: 7223731 (2007-05-01), Lawler
patent: 7368548 (2008-05-01), Dahary et al.
patent: 2002/0155615 (2002-10-01), Novikov et al.
patent: 2003/0118585 (2003-06-01), Muller et al.
patent: 2003/0176666 (2003-09-01), Sutcliffe et al.
patent: 2004/0054268 (2004-03-01), Esenaliev et al.
patent: 2004/0101876 (2004-05-01), Mintz et al.
patent: 2004/0127777 (2004-07-01), Ruchti et al.
patent: 2004/0142325 (2004-07-01), Mintz et al.
patent: 2004/0248157 (2004-12-01), Ayalon-Soffer et al.
patent: 2004/0265799 (2004-12-01), Novik et al.
patent: 2005/0123538 (2005-06-01), Shemesh et al.
patent: 2005/0186600 (2005-08-01), Sella-Tavor et al.
patent: 2005/0233960 (2005-10-01), Kong-Beltran et al.
patent: 2006/0068405 (2006-03-01), Diber et al.
patent: 2007/0082337 (2007-04-01), Sorek et al.
patent: 125023 (1984-11-01), None
patent: 184187 (1985-06-01), None
patent: 171496 (1986-02-01), None
patent: 173494 (1986-03-01), None
patent: 0519596 (1992-12-01), None
patent: 0770349 (1997-05-01), None
patent: 2322941 (1998-09-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 90/02809 (1990-03-01), None
patent: WO 91/00906 (1991-01-01), None
patent: WO 91/06667 (1991-05-01), None
patent: WO 91/10741 (1991-07-01), None
patent: WO 91/17271 (1991-11-01), None
patent: WO 92/01047 (1992-01-01), None
patent: WO 92/03917 (1992-03-01), None
patent: WO 92/03918 (1992-03-01), None
patent: WO 92/09690 (1992-06-01), None
patent: WO 92/15679 (1992-09-01), None
patent: WO 92/18619 (1992-10-01), None
patent: WO 92/20791 (1992-11-01), None
patent: WO 93/01288 (1993-01-01), None
patent: WO 94/10300 (1994-05-01), None
patent: WO 98/55510 (1998-12-01), None
patent: WO 99/18208 (1999-04-01), None
patent: WO 99/51773 (1999-10-01), None
patent: WO 02/12341 (2002-02-01), None
patent: WO 03/020953 (2003-03-01), None
patent: WO 2004/092338 (2004-10-01), None
patent: WO 2004/096979 (2004-11-01), None
patent: WO 2004/096980 (2004-11-01), None
patent: WO 2005/033133 (2005-04-01), None
patent: WO 2005/068618 (2005-07-01), None
patent: WO 2005/071058 (2005-08-01), None
patent: WO 2005/071059 (2005-08-01), None
patent: WO 2005/111634 (2005-11-01), None
patent: WO 2005/113596 (2005-12-01), None
Lawler et al., J. Cell. Biol. 103:1635-1648, 1986.
Chen et al., Mol Cell Prot 1:304-313, 2002.
Tolsma et al., J. Cell Biol. 122:497-511, 1993.
Chen et al., Biochemistry 37:9976-9982, 1998.
“Agencourt—6578352 NIH—MGC—41Homo SapienscDNA Clone IMAGE: 5467535 5′, mRNA Sequence”, Database EMBL ′Online!, Database Accession No. BM556795, 2002.
“Agencourt—785234 NIH—MGC—67Homo SapienscDNA Clone IMAGE: 6140098 5′, mRNA Sequence”, Database EMBL ′Online!, Database Accession No. BU169315, 2002.
“Agencourt—7952308 NIH—MGC—72Homo SapienscDNA Clone IMAGE: 6149711 5′, mRNA Sequence”, Database EMBL ′Online!, Database Accession No. BU171488, 2002.
“OTTHUMP00000031654 (Fragment)”, Database EMBL, Database Accession No. Q9BQP0, 2001. Abstract.
Abounader et al. “In Vivo Targeting of SF/HGF and C-Met Expression Via U1snRNA/Ribozymes Inhibits Glioma Growth and Angiogenesis and Promotes Apoptosis”, The FASEB Journal, 16: 108-110, 2001.
Adams et al. “Initial Assessment of Human Gene Diversity and Expression Patterns Based Upon 83 Million Nucleotides of cDNA Sequence”, Nature, 377(Suppl.): 3-173, Sep. 28, 1995.
Aggarwal “BB Signalling Pathways of the TNF Superfamily: A Double-Edged Sword”, Nature Reviews Immunology, 3(9): 745-755, 2003.
Aigner et al. “Expression of A Truncated 100 kDa HER2 Splice Variants Acts as An Endogenous Inhibitor of Tumour Cell Proliferation”, Oncogene, 20(17): 2101-2111, 2001.
Akhurst “TGF-β Antagonists: Why Suppress A Tumor Suppressor?”, The Journal of Clinical Investigation, 109(12): 1533-1536, 2002.
Altschul et al. “Basic Local Alignment Search Tool”, Journal of molecular Biology, 215: 403-410, 1990.
Asadullah et al. “Interleukin-10 Therapy-Review of A New Approach”, Pharmacological Review, 55(2): 241-269, 2003.
Attisano et al. “Signal Transduction by the TGF-β Superfamily”, Science, 296(5573): 1646-1647, 2002.
Audic et al. “The Significance of Digital Gene Expression Profiles”, Genome Research, 7: 986-995, 1997.
Azios et al. “Expression of Herstatin, An Autoinhibitor of HER-2/Neu, Inhibits Transactivation of HER-3 by HER-2 and Blocks EGF Activation of the EGF Receptor”, Oncogene, 20(37): 5199-5232, 2001.
Baker et al. “A Randomized Phase 2 Study of the Thrombospondin-Mimetic.Peptide ABT-510 in Patients With Advanced Soft Tissue Sarcoma (STS)”, Journal of Clinical Onoclogy, Proceedings of the ASCO Annual Meeting 2005, 23(16 Suppl.): 9013, Jun. 1, 2005. Abstract.
Benson et al. “GenBank”, Nucleic Acids Research, 25(1): 1-6, 1997. p. 1-5.
Bieche et al. “Overexpression of BRCA2 Gene in Sporadic Breast Tumours”, Oncogen, 18: 5232-5238, 1999.
Bihl et al. “Identification of a Novel IL-6 Isoform Binding to the Endogenous IL-6 Receptor”, American Journal of Respiratory Cell and Molecular Biology, 27: 48-56, 2002.
Birchmeier et al. “Met, Metastasis, Motility and More”, Nature Reviews: Molecular Cell Biology, 4: 915-925, 2003.
Blazar et al. “Ligation of 4-IBB (CDw137) Regulates Graft-Versus-Host Disease, Graft-Versus-Leukemia, and Graft Rejection in Allogeneic Bone Marrow Transplant Recipients”, The Journal of Immunology, 166(5): 3174-3183, 2001.
Boguski “Biosequence Exegesis”, Science, 286: 453-455, 1999.
Boguski et al. “ESTablishing A Human Transcript Map”, Nature Genetics, 10: 369-371, 1995.
Bonfield et al. “A New DNA Sequence Assembly Program”, Nucleic Acids Research, 23(24): 4992-4999, 1995.
Bornstein “Diversity of Function Is Inherent in Matricellular Proteins: An Appraisal of Thrombospondin 1”, The Journal of Cell Biology, 130(3): 503-506, Aug. 1995.
Bornstein “Thrombospondins: Structure and Regulation of Expression”, The FASEB Journal, 6: 3290-3299, 1992.
Brattain et al. “The Type II Transforming Growth Factor-β Receptor as A Tumor-Suppressor Gene”, Current Opinion in Oncology, 8(1): 49
Beck Nili
Bernstein Jeanne
Dahary Dvir
Freilich Shiri
Levanon Erez
Compugen Ltd.
Steadman David J
LandOfFree
Human thrombospondin polypeptide does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human thrombospondin polypeptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human thrombospondin polypeptide will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4209003